SG48460A1 - External therapeutic composition for dermatitis - Google Patents

External therapeutic composition for dermatitis

Info

Publication number
SG48460A1
SG48460A1 SG1996010182A SG1996010182A SG48460A1 SG 48460 A1 SG48460 A1 SG 48460A1 SG 1996010182 A SG1996010182 A SG 1996010182A SG 1996010182 A SG1996010182 A SG 1996010182A SG 48460 A1 SG48460 A1 SG 48460A1
Authority
SG
Singapore
Prior art keywords
dermatitis
therapeutic composition
external therapeutic
clathrate
aqueous solution
Prior art date
Application number
SG1996010182A
Other languages
English (en)
Inventor
Akira Yamada
Hajime Yamada
Original Assignee
Cac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cac Corp filed Critical Cac Corp
Publication of SG48460A1 publication Critical patent/SG48460A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Carriers, Traveling Bodies, And Overhead Traveling Cranes (AREA)
SG1996010182A 1995-12-11 1996-06-29 External therapeutic composition for dermatitis SG48460A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7346006A JP2920611B2 (ja) 1995-12-11 1995-12-11 皮膚炎の治療外用剤

Publications (1)

Publication Number Publication Date
SG48460A1 true SG48460A1 (en) 1998-04-17

Family

ID=18380498

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996010182A SG48460A1 (en) 1995-12-11 1996-06-29 External therapeutic composition for dermatitis

Country Status (14)

Country Link
US (1) US5885978A (ja)
EP (1) EP0780129B1 (ja)
JP (1) JP2920611B2 (ja)
KR (1) KR0181763B1 (ja)
CN (1) CN1153571C (ja)
AT (1) ATE290883T1 (ja)
AU (1) AU705996B2 (ja)
CA (1) CA2173403C (ja)
DE (1) DE69634472T2 (ja)
DK (1) DK0780129T3 (ja)
ES (1) ES2240987T3 (ja)
HK (1) HK1004979A1 (ja)
SG (1) SG48460A1 (ja)
TW (1) TW431889B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
IT1319665B1 (it) * 2000-11-17 2003-10-23 Pharma Biotech Ltd Addotti di corticosteroidi con polimeri polisaccaridici naturali.
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
WO2003101460A1 (fr) 2002-06-03 2003-12-11 Cac Corporation Preparations a usage externe pour le traitement de la dermatite
FR2842106B1 (fr) * 2002-07-11 2006-07-14 Centre Nat Rech Scient Dispersions aqueuses de particules nanometriques ou micrometriques pour l'encapsulation de composes chimiques
KR100564153B1 (ko) * 2002-11-28 2006-03-27 주식회사 에이치 엔 비티 아토피성 피부염을 개선시키는 조성물
EP1761283A2 (en) 2004-06-07 2007-03-14 California Institute Of Technology Biodegradable drug-polymer delivery system
AU2005252436B2 (en) * 2004-06-11 2010-11-11 The University Of Manchester Method for ameliorating an inflammatory skin condition
JP5456802B2 (ja) * 2012-01-23 2014-04-02 株式会社Cac 細胞遊走促進剤及び創傷治療用の経皮吸収剤
JP6313118B2 (ja) * 2014-05-16 2018-04-18 株式会社Cac IgE抑制剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5231019B2 (ja) * 1973-10-16 1977-08-12
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS61246130A (ja) * 1985-04-24 1986-11-01 Japan Fine Chem Kk 水性皮膚及び毛髪化粧料
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
DE68901043D1 (de) * 1988-01-14 1992-04-30 Akzo Nv Waessriges pharmazeutisches praeparat.
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
JPH0795311B2 (ja) * 1988-06-30 1995-10-11 日本電気株式会社 二重化処理装置
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
JP2681527B2 (ja) * 1990-02-15 1997-11-26 ジャパンファインケミカル株式会社 細胞活性促進外用剤
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
JP2578048B2 (ja) * 1992-05-22 1997-02-05 株式会社 シーエーシー 循環瀘過装置
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
JP3535883B2 (ja) * 1993-06-25 2004-06-07 井関農機株式会社 作業機連結装置
JPH0756417A (ja) * 1993-08-09 1995-03-03 Ricoh Co Ltd 回転型現像装置
JP2772619B2 (ja) * 1994-06-28 1998-07-02 株式会社シーエーシー 多糖類水溶液用循環風呂

Also Published As

Publication number Publication date
TW431889B (en) 2001-05-01
CA2173403A1 (en) 1997-06-12
EP0780129B1 (en) 2005-03-16
JP2920611B2 (ja) 1999-07-19
AU5056096A (en) 1997-06-19
US5885978A (en) 1999-03-23
ATE290883T1 (de) 2005-04-15
EP0780129A2 (en) 1997-06-25
DE69634472D1 (de) 2005-04-21
KR970032871A (ko) 1997-07-22
ES2240987T3 (es) 2005-10-16
CN1151866A (zh) 1997-06-18
CA2173403C (en) 2000-05-16
KR0181763B1 (ko) 1999-05-01
HK1004979A1 (en) 1998-12-18
DE69634472T2 (de) 2006-02-16
JPH09157171A (ja) 1997-06-17
AU705996B2 (en) 1999-06-03
EP0780129A3 (en) 2000-07-19
DK0780129T3 (da) 2005-06-20
CN1153571C (zh) 2004-06-16

Similar Documents

Publication Publication Date Title
FI961098A (fi) Menetelmä progestogeniä ja estrogeniä sisältävän korvikkeen valmistamiseksi
SG48460A1 (en) External therapeutic composition for dermatitis
HU9200048D0 (en) Process for treating androgene deseases
DE69737510D1 (de) Verwendung eines unverkapselten anti-krebs-wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation
IL133585A0 (en) Soluble prodrugs of paclitaxel
MX9704988A (es) Derivados de hidroxilamina utiles para mejorar la produccion del acompañante molecular y la preparacion de los mismos.
PL301841A1 (en) Pharmaceutical agent and method of obtaining same
DE69320646T2 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ID28160A (id) Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.
FR08C0001I1 (ja)
Sallis et al. Calcium metabolism in relation to vitamin D and adrenal function in the chick
NO981282L (no) Calcitriolderivater og deres anvendelser
DE69328635T2 (de) Verwendung eines stoffgemisches enthaltend alpha hydroxy organische säure zur herstellung eines arzneimittels zur behandlung von kleinen mundgeschwüren
UA35566C2 (uk) Лікарський засіб для профілактики і лікування порушень ліпоїдного і холестеринового обміну речовин і спосіб профілактики і лікування цих порушень
ES2165382T3 (es) Agentes antiateroescleroticos.
UA7076A (uk) Спосіб лікування нефротичної форми гломерулонефриту у дітей
UA49572A (uk) Спосіб лікування затяжних пневмоній
UA28777A (uk) Спосіб лікування алкогольного делірію, ускладненого набряком-набуханням головного мозку
UA30798A (uk) Спосіб пролонгованої терапії онкологічних хворих
NO962535L (no) Di-tert-butylfenolforbindelser anvendbare som antiflammatoriske midler